Please use this identifier to cite or link to this item:
Title: Toxicological and pharmacokinetic analysis at therapeutic dose of SRS27, an investigational anti-asthma agent
Authors: Lim, JCW
Sagineedu, SR
Yong, ACH
Sidik, SM
Wong, WSF 
Stanslas, J
Keywords: Acute toxicity
Andrographolide analogues
Anti-Asthmatic Agents
Biological Availability
Mice, Inbred BALB C
Issue Date: 1-Jan-2021
Publisher: Springer Science and Business Media LLC
Citation: Lim, JCW, Sagineedu, SR, Yong, ACH, Sidik, SM, Wong, WSF, Stanslas, J (2021-01-01). Toxicological and pharmacokinetic analysis at therapeutic dose of SRS27, an investigational anti-asthma agent. Naunyn-Schmiedeberg's Archives of Pharmacology 394 (1) : 95-105. ScholarBank@NUS Repository.
Abstract: SRS27, an andrographolide analogue, had been proven to have therapeutic properties at a dose of 3 mg/kg in both in vitro and in vivo asthma models of our previous study. The present study focuses on the pharmacokinetic and toxicity profile of this compound to provide further evidence for the development of this compound as an anti-asthma agent. A simple pharmacokinetic study was performed in female BALB/c mice to measure blood plasma concentration of the compound at therapeutic dose. At a single dose of 3 mg/kg, SRS27 had a relatively short half-life but was able to achieve a concentration range of 13–19 μM that is related to its in vitro bioactivities. With regard to toxicity profile, SRS27 appears to be safe, as no histopathological changes were observed in the liver, kidneys and ovaries of SRS27-treated female BALB/c mice. In addition, there was no significant change in the mean body weight and organ weight of the animals in the SRS27-treated groups compared with the vehicle-treated control group at the end of the treatment. This fully supports the absence of any significant changes in peripheral blood leukocyte counts of SRS27-treated mice. Rewardingly, this acute toxicity study also revealed that SRS27 has a wide therapeutic window as no toxicity symptoms were detected with a dose up to 60 mg/kg daily when tested for 14 days. These results provide strong justification for further investigation of SRS27 as a potential new anti-asthma agent.
Source Title: Naunyn-Schmiedeberg's Archives of Pharmacology
ISSN: 00281298
DOI: 10.1007/s00210-020-01966-3
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Andrographolide SRS27 asthma 2020.pdf2.47 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.